{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:31Z","timestamp":1791924451369,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jgar.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:47:33Z","timestamp":1791848853000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the evidence for use of cefiderocol as part of combination therapies: a systematic review of in vitro, in vivo, and clinical studies"],"prefix":"10.1016","author":[{"given":"Marco","family":"Meroi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio del Castillo","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Scardellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8057-3092","authenticated-orcid":false,"given":"Alessandra","family":"Nazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Savoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Tacconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-0261","authenticated-orcid":false,"given":"Matteo","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-1200","authenticated-orcid":false,"given":"Elda","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.09.016_bib0001","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cmi.2021.05.002","article-title":"Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations","volume":"28","author":"Carrara","year":"2022","journal-title":"Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0006","doi-asserted-by":"crossref","unstructured":"Tsuji M, Kohira N, Nakamura R, Sato T, Yamano Y. S-649266, a Novel Siderophore Cephalosporin: in vitro combination effect of S-649266 and other antibiotics against Gram-negative bacteria. Poster presented at: 26th ECCMID; 2016 Apr 9; Amsterdam, n.d.","DOI":"10.26226\/morressier.56d6be7ad462b80296c97db1"},{"key":"10.1016\/j.jgar.2026.09.016_bib0007","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/antibiotics12050858","article-title":"Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria","volume":"12","author":"Palombo","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0008","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"10.1016\/j.jgar.2026.09.016_bib0009","first-page":"S325","article-title":"723. Synergistic effect of cefiderocol combined with other antibiotics against cefiderocol high MIC isolates from the multi-national SIDERO-WT studies","volume":"6","author":"Yamano","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/cells13161315","article-title":"Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria","volume":"13","author":"Lewis","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jgar.2026.09.016_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00164-24","article-title":"Glycine restores the sensitivity to antibiotics in multidrug-resistant bacteria","volume":"12","author":"Giordano","year":"2024","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.jgar.2026.09.016_bib0012","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10096-023-04732-4","article-title":"Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility\/resistance to cefiderocol: which are the best present and future therapeutic alternatives?","volume":"43","author":"Le Terrier","year":"2024","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106417","article-title":"Zidebactam restores cefiderocol sensitivity in resistant bacteria","volume":"90","author":"Xu","year":"2025","journal-title":"Journal of Infection"},{"key":"10.1016\/j.jgar.2026.09.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.166","article-title":"514. The impact of xeruborbactam on in vitro activity of cefiderocol against a panel of acinetobacter baumannii enriched in isolates with reduced cefiderocol susceptibility","volume":"12","author":"Hara","year":"2025","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1298","article-title":"P-1110. The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Enterobacterales Enriched with Isolates with Reduced Cefiderocol Susceptibility","volume":"12","author":"Hara","year":"2025","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0016","doi-asserted-by":"crossref","first-page":"S662","DOI":"10.1093\/ofid\/ofaa439.1478","article-title":"1295. Activity of SPR206, a polymyxin b derivative, compared to colistin alone and in combination against multidrug-resistant pseudomonas aeruginosa strains","volume":"7","author":"Abdul-Mutakabbir","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0017","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","article-title":"In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii","volume":"41","author":"Ni","year":"2022","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41429-024-00801-8","article-title":"Activity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii","volume":"78","author":"Yin","year":"2025","journal-title":"The Journal of Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0019","unstructured":"Stolfa S, Romanelli F, Ronga L, Bavaro DF, Stufano M, Dalfino L, et al. In vitro activity of cefiderocol in combination with colistin, fosfomycin and tigecycline against acinetobacter baumannii. Abstracts of the 31st european congress of clinical microbiology & infectious diseases (ECCMID), Online: 2021."},{"key":"10.1016\/j.jgar.2026.09.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa439.1806","article-title":"1626. Synergistic effect of cefiderocol with other antibiotics against PER-producing acinetobacter baumannii isolates from the multinational SIDERO-WT studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0021","first-page":"1681","article-title":"Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms","volume":"11","author":"Bianco","year":"2022","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"10.1016\/j.jgar.2026.09.016_bib0022","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcb.30424","article-title":"Determination of potential combination of non-\u03b2-lactam, \u03b2-lactam, and \u03b2-lactamase inhibitors\/\u03b2-lactam enhancer against class D oxacillinases producing Acinetobacter baumannii: Evidence from in-vitro, molecular docking and dynamics simulation","volume":"124","author":"Gopikrishnan","year":"2023","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.jgar.2026.09.016_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.2135","article-title":"2517. Activity of sulbactam-durlobactam, antibacterial combinations, and comparators against a challenge set of 66 acinetobacter baumannii-calcoaceticus species complex isolates","volume":"10","author":"Huband","year":"2023","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0024","doi-asserted-by":"crossref","first-page":"ofac484","DOI":"10.1093\/ofid\/ofac484","article-title":"Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration","volume":"9","author":"Kobic","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00930-24","article-title":"Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp","volume":"12","author":"Wong","year":"2024","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.jgar.2026.09.016_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s44259-025-00079-2","article-title":"Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR","volume":"3","author":"You","year":"2025","journal-title":"Npj Antimicrobials and Resistance"},{"key":"10.1016\/j.jgar.2026.09.016_bib0027","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10096-022-04408-5","article-title":"Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era","volume":"41","author":"Bianco","year":"2022","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0028","article-title":"Delaying cefiderocol resistance development in NDM-producing enterobacter cloacae complex by combining cefiderocol with aztreonam in vitro","author":"G\u00f6pel","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jgar.2026.09.016_bib0029","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","article-title":"In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects","volume":"41","author":"Bianco","year":"2021","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/1120009X.2022.2090615","article-title":"Activity of cefiderocol and synergy of novel \u03b2-lactam-\u03b2-lactamase inhibitor-based combinations against metallo-\u03b2-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020)","volume":"35","author":"Boattini","year":"2023","journal-title":"Journal of Chemotherapy (Florence, Italy)"},{"key":"10.1016\/j.jgar.2026.09.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03496-22","article-title":"Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum \u03b2-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35","volume":"11","author":"Moon","year":"2023","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.jgar.2026.09.016_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jiph.2023.11.003","article-title":"High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant klebsiella pneumoniae from inpatients attending a single hospital in the united arab emirates","volume":"16","author":"Daoud","year":"2023","journal-title":"Journal of Infection and Public Health"},{"key":"10.1016\/j.jgar.2026.09.016_bib0033","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10096-023-04671-0","article-title":"Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal","volume":"42","author":"Daoud","year":"2023","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0034","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/antibiotics14020210","article-title":"Combating Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa: The Fractional Inhibitory Concentration Index as a Tool to Evaluate Antibiotic Synergy","volume":"14","author":"Granata","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jgar.2024.01.021","article-title":"Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa","volume":"37","author":"Ferretti","year":"2024","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"10.1016\/j.jgar.2026.09.016_bib0036","unstructured":"El Haj C, Agust\u00ed E, Benavent E, Tubau Quintano MF, C\u00e0mara J, Rigo-Bonnin R, et al. Efficacy of cefiderocol alone and combined with colistin against biofilms by MDR\/XDR pseudomonas aeruginosa: A dynamic study. Abstracts of the 34th european congress of clinical microbiology & infectious diseases (ECCMID), Barcelona, Spain: 2024."},{"key":"10.1016\/j.jgar.2026.09.016_bib0037","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/antibiotics13121236","article-title":"Efficacy of Cefiderocol Against Endophthalmitis Isolates","volume":"13","author":"Schilling","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0038","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1038\/s41467-023-40828-3","article-title":"Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance","volume":"14","author":"Wang","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.jgar.2026.09.016_bib0039","article-title":"Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin b, or trimethoprim-sulfamethoxazole against multidrug-resistant stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-022-00986-0","article-title":"Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0041","article-title":"Biofilm Microenvironment Activated Antibiotic Adjuvant for Implant-Associated Infections by Systematic Iron Metabolism Interference","volume":"11","author":"Ding","year":"2024","journal-title":"Advanced Science"},{"key":"10.1016\/j.jgar.2026.09.016_bib0042","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jac\/dkad032","article-title":"In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii","volume":"78","author":"Gill","year":"2023","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0043","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/antibiotics12061048","article-title":"Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study","volume":"12","author":"Dalfino","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0045","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2026.09.016_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107190","article-title":"Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience","volume":"64","author":"Russo","year":"2024","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.jgar.2026.09.016_bib0047","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0048","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: An italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0049","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections","volume":"51","author":"Gavaghan","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2026.09.016_bib0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/antibiotics13111001","article-title":"Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients\u2019 Prognosis","volume":"13","author":"Frattari","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0051","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","article-title":"Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study","volume":"43","author":"Oliva","year":"2024","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0052","doi-asserted-by":"crossref","first-page":"e03108","DOI":"10.1128\/spectrum.03108-23","article-title":"Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections","volume":"12","author":"El Ghali","year":"2024","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.jgar.2026.09.016_bib0053","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S475462","article-title":"Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study","volume":"17","author":"Clancy","year":"2024","journal-title":"Infection and Drug Resistance"},{"key":"10.1016\/j.jgar.2026.09.016_bib0054","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad329","article-title":"Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic","volume":"10","author":"Giannella","year":"2023","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.jgar.2026.09.016_bib0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: Single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0056","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/antibiotics13111007","article-title":"Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study","volume":"13","author":"Buonomo","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2026.09.016_bib0057","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1016\/j.jgar.2026.09.016_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:05:50Z","timestamp":1791921950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S2213716526001840"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.09.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the evidence for use of cefiderocol as part of combination therapies: a systematic review of in vitro, in vivo, and clinical studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}